Increased titres of anti-human heat shock protein 60 predict an adverse one year prognosis in patients with acute cardiac chest pain. Issue 9 (15th August 2005)

• Record Type: Journal Article
• Authors: Birnie, D H; Vickers, L E; Hillis, W S; Norrie, J; Cobbe, S M
• Is Part Of: Heart. Volume 91:Issue 9(2005)
• Page Start: 1148
• Page End: 1153
• Publication Date: 2005-08-15
• Subjects: BSA, bovine serum albumin -- CABG, coronary artery bypass grafting -- CHD, coronary heart disease -- CI, confidence interval -- CRP, C reactive protein -- ELISA, enzyme linked immunosorbent assay -- hsp, heat shock protein -- huhsp, human heat shock protein -- mhsp, mycobacterial heat shock protein -- MI, myocardial infarction -- PBS, phosphate buffered saline -- PTCA, percutaneous transluminal coronary angioplasty; atherosclerosis -- inflammation -- prognosis -- antibodies -- heat shock protein 60 -- coronary heart disease; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/hrt.2004.040485
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Objective: To assess whether antibodies to human heat shock protein 60 (anti-huhsp60) or to mycobacterial heat shock protein 65 (anti-mhsp65) predict an adverse one year prognosis in patients admitted with acute cardiac chest pain. Design: Prospective observational study. Setting: Teaching hospital. Patients: 588 consecutive emergency admissions of patients with acute chest pain of suspected cardiac origin. Main outcome measures: Anti-huhsp60 and anti-mhsp65 titres were assayed on samples drawn on the morning after admission. The end points after discharge were coronary heart disease death, non-fatal myocardial infarction, coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, angiogram, or readmission with further cardiac ischaemic chest pain. Results: During follow up after discharge (mean of 304 days, range 1–788 days), 277 patients had at least one of the study outcomes. Patients with increased titres of anti-huhsp60 had an adverse prognosis (hazard ratio 1.56 (95% confidence interval 1.09 to 2.23) comparing highest versus lowest quartiles, p = 0.015). Anti-mhsp65 titres were not predictive. Conclusions: Patients admitted with acute cardiac chest pain and increased titres of anti-huhsp60 had an adverse one year prognosis.